<DOC>
	<DOCNO>NCT00527033</DOCNO>
	<brief_summary>Examine dose YM178 best term efficacy , safety tolerability compare placebo</brief_summary>
	<brief_title>A Study YM178 Patients With Symptomatic Overactive Bladder</brief_title>
	<detailed_description>To investigate dose-response relationship YM178 term efficacy , safety tolerability , also superiority YM178 placebo .</detailed_description>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>Patients 20 year suffer overactive bladder Pregnant breastfeed woman Any clinically significant abnormal condition opinion investigator make patient unsuitable study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>YM178</keyword>
	<keyword>Urinary Bladder , Overactive</keyword>
</DOC>